Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucan-sartuzumab
- Development stage
- Unknown
- Lead developer
- Lishui City Central Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lucan-Sartuzumab is a humanized monoclonal antibody being investigated for the treatment of advanced, unresectable, or metastatic intrahepatic cholangiocarcinoma (ICC). It is currently the primary therapeutic agent in the SPICE Trial (ChiCTR2600119932), a single-arm Phase II clinical study sponsored by Lishui Central Hospital in China. The trial evaluates the efficacy and safety of Lucan-Sartuzumab when administered in a multimodal regimen alongside cryoablation and immune checkpoint inhibitors (immunotherapy) for patients who have progressed after at least one prior systemic therapy. As a humanized antibody, Lucan-Sartuzumab is designed to target specific tumor-associated antigens, potentially facilitating an enhanced anti-tumor immune response and improving outcomes in biliary tract cancers.
- Other names
- Lucan-Sartuzumab
Beyond the preview
Go deeper on lucan-sartuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucan-sartuzumab.